Demystifying Valeant And Philidor
This article was originally published in Scrip
You may also be interested in...
The plagued specialty pharma has been rumored to have at least one suitor, but analysts are skeptical and expect multiple divestitures will be required if the company is going to gain back some of its losses.
Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.
The biotech is shifting gears after clinical hold on its lead drug was unlikely to be lifted, but the early-stage candidate that it's placing its hopes on is raising red flags for analysts and investors.